Cymbiotika Liposomal Vitamin D3 + K2 + CoQ10 Review: A Real Absorption Study, and the Questions It Does Not Answer

Brand Guides
November 14, 2026

Vitamin D3 with K2 is one of the most repeated combinations in the supplement world. The pitch is simple. D3 helps you absorb calcium, K2 tells the calcium where to go, into bone instead of arteries, and CoQ10 adds cellular energy on top. It sounds complete. The problem is that almost none of it has been tested as a combination. No large trial has compared D3 plus K2 against D3 alone for fractures or artery calcification. And almost no liposomal brand has published a human absorption trial of its own product.

Cymbiotika just changed the second part. In January 2026, researchers ran a randomized, double-blind crossover trial of this exact product against a standard D3 tablet, published in Frontiers in Nutrition. The liposomal formula delivered about twice as much vitamin D3 into the blood over 48 hours. That is a real result, and it is rare in this industry. It is also a small, company-funded, single-dose study that measured absorption, not health outcomes. This review looks at what the study proves, what the K2 and CoQ10 add, and whether the price makes sense.

Disclosure: I'm affiliated with Cymbiotika, but I only recommend things I can actually stand behind so here's my honest breakdown.

The short answer

The absorption study is genuine and well designed for what it is, but it is 12 people, one dose, and funded by Cymbiotika, with two authors employed by the company. The product delivers 4,000 IU of D3, 620 mcg of K2 as MK-4 and MK-7, and 40 mg of ubiquinol CoQ10 per packet. That 4,000 IU sits exactly at the adult tolerable upper intake level for vitamin D, not at the recommended daily amount of 600 IU. K2 has decent evidence for bone turnover markers and mixed evidence for arteries, and no trial shows D3 plus K2 beats D3 alone. The 40 mg of CoQ10 is well below the 100 to 300 mg doses used in most CoQ10 trials, and the ubiquinol advantage over ubiquinone is not settled. At $76 a box for 28 packets, you are paying for the delivery system and the convenience, not for doses that match the clinical trials.

The research gap this product actually fills

Two gaps sit behind this formula, and they are different gaps. The first is the delivery question. Vitamin D3 is fat soluble, so its absorption depends on bile, dietary fat, and gut health, and it varies a lot from person to person. Liposomal brands claim their phospholipid bubbles fix this, but the claim usually rests on mechanism and marketing, not on a trial of the product being sold. The second gap is the combination question. D3 plus K2 is sold everywhere, yet no trial has randomized people to D3 plus K2 versus D3 alone and measured fractures, bone density, or artery calcification. The combination is a plausible mechanism, not a finding. This product now has real evidence for the first gap and none for the second.

The 2026 study: what was actually tested

The trial was published in Frontiers in Nutrition in 2026 and registered as ISRCTN39055102. Twelve healthy adults finished it, average age 34, average BMI 24.8. Each person took both products in random order, two weeks apart, after an overnight fast, and blood was drawn for 48 hours. Each person served as their own control, which is the strongest design for a study this small. The liposomal arm was one sachet of the Cymbiotika product: 4,000 IU of D3, 620 mcg of K2, and 40 mg of CoQ10. The comparison arm was a standard tablet with the same D3 and K2 doses, no CoQ10, and no liposomal carrier.

The results were clear. Total exposure over 48 hours, measured as area under the curve, was 199 ng.h/mL for the liposomal formula versus 106 for the tablet, about 1.9 times higher. Peak concentration was 8.4 versus 6.0 ng/mL. Liposomal levels were still above baseline at 48 hours, while the tablet arm had returned to baseline.

What the study proves: this complete product gets more D3 into the blood in the first two days than a matched tablet. What it does not prove: first, long-term vitamin D status, because it measured cholecalciferol itself, not 25(OH)D, the storage form doctors test. Second, better health outcomes, because nobody's bones, immunity, or arteries were measured. Third, that the liposome is the reason, because the two arms also differed in dosage form, gel versus tablet, and the liposomal arm contained CoQ10. The authors say this themselves. Fourth, anything about older people, people with gut conditions, or people who are actually deficient, because the participants were healthy young adults. And the 1.9 figure is an average from 12 people with wide confidence intervals. The authors call the findings hypothesis-generating for larger confirmatory studies, and that is the right label.

The study was funded by Cymbiotika LLC, and two authors were employed by the company. The paper states the funder had no role in design, analysis, or writing. That is worth knowing rather than a reason to dismiss the study outright. The crossover design, the blinding, the preregistration, and the authors' own careful limits in the discussion are all good signs. But an independent replication in more people, over weeks instead of hours, measuring 25(OH)D, is what would settle it.

What is in the packet

One 5 mL liquid packet, tangerine flavour, taken daily in the morning, with or without food. Per packet: vitamin D3 4,000 IU (100 mcg) from lichen, so plant-based; vitamin K2 620 mcg total, as both MK-4 and MK-7; CoQ10 40 mg as ubiquinol; and 60 mg of phosphatidylcholine from sunflower lecithin, which forms the liposomes. Other ingredients are glycerin, water, organic cassava syrup, pectin, vanilla extract, malic acid, tangerine oil, vitamin E, sodium alginate, rowanberry extract, vanilla powder, calcium lactate, and beta carotene for colour. It is gluten free, soy free, non-GMO, and plant-based. The box holds 28 packets.

One warning about formats. Cymbiotika also sells this formula as a 60 mL bottle, and that older format has different doses: 5,000 IU of D3, 120 mcg of MK-7, 500 mcg of MK-4, 80 mcg of selenium, and 20 mg of ubiquinol, in 30 servings of 2 mL. The packets are the current format and the one in the study, and they doubled the CoQ10, from 20 mg in the bottle to 40 mg. Check the label if you buy the bottle, because the numbers are not the same.

Vitamin D3, and the dose question

The recommended dietary allowance for vitamin D is 600 IU a day for adults up to age 70, and 800 IU after 70. The tolerable upper intake level is 4,000 IU a day. This product sits exactly at that ceiling. The Endocrine Society's 2024 guideline recommends empiric vitamin D, meaning above the recommended intake without testing, for children and teens, adults 75 and older, pregnant people, and people with high-risk prediabetes. For generally healthy adults under 75, it suggests following the recommended intake and advises against routine 25(OH)D testing.

That does not make 4,000 IU unsafe for a healthy adult. It is the established upper limit, and studies use it often. But it does mean the dose is a deliberate choice to sit at the top of the range, and it leaves no room for other D3 sources. If you take a multivitamin or another D3 product as well, your total can pass the upper limit. Vitamin D is fat soluble and accumulates, and too much raises blood calcium. If you supplement at the upper limit, a 25(OH)D blood test before starting and after a few months is the only way to know where you land. The guideline advises against routine testing for healthy adults taking recommended amounts, but testing is reasonable when you take 4,000 IU a day.

Vitamin K2: a real mechanism, thinner outcome data

K2 activates two proteins. Osteocalcin binds calcium into the bone matrix. Matrix Gla protein, or MGP, inhibits calcium from depositing in vessel walls. That is why K2 is called the traffic cop for calcium, and the mechanism is solid. The outcome data is thinner.

For bone, a November 2025 meta-analysis of 9 randomized trials with 2,570 postmenopausal women with osteoporosis found K2 improved bone turnover markers: higher osteocalcin, higher bone-specific alkaline phosphatase, and lower undercarboxylated osteocalcin. The authors said long-term studies are still needed to confirm benefits like bone mineral density. Markers moved. Bones, so far, are less certain.

For arteries, the picture is mixed and genuinely interesting. The AVADEC trial, published in Circulation in 2022, randomized 365 men averaging 71 years old, all with calcified aortic valves, to 720 mcg of MK-7 plus vitamin D or placebo for two years. Valve calcification rose by 275 Agatston units on treatment and 292 on placebo, a difference that was not significant. A follow-up analysis of coronary calcium in 304 of those men found no significant difference overall, but a possible signal in the subgroup who started with heavy calcification, where progression was 288 versus 380 units. The authors called that hypothesis-generating. A 2023 pooled analysis of 14 trials and 1,533 people found vitamin K slowed coronary calcium progression by an average of 17.4 Agatston units, a small effect. Then a 2026 confirmatory trial, DANCODE, randomized 398 people with heavy coronary calcium to the same K2 plus D combination, and calcium scores rose 52 units less on treatment than on placebo over two years. So the current reading is that K2 may slow calcification in people who already have a lot of it, and it does not reverse existing calcification. No trial has shown fewer heart attacks or deaths.

The dose in the artery trials, 180 to 720 mcg of MK-7, brackets this product's 620 mcg of total K2, so the amount is in the right range. MK-7 lasts days in the blood while MK-4 lasts hours, which is why most trials use MK-7. This product includes both, though the label does not split the 620 mcg between them.

CoQ10: the smallest dose in the formula

CoQ10 is made by the body and used in mitochondria to produce energy. Levels fall with age and with statin use, which is why people supplement. The form debate is worth a clear answer, because it is marketed hard. Ubiquinol is the reduced form, ubiquinone the oxidized form. About 95 to 98 percent of CoQ10 in blood circulates as ubiquinol no matter which form you swallow, because the body converts it. Head-to-head absorption trials are mixed. A 2019 crossover trial of seven products in 14 adults found absorption varied about 10-fold between products, and the deciding factor was formulation, specifically whether the CoQ10 crystals had been dispersed, not which form was on the label. A 2020 crossover in 21 adults aged 65 to 74 found ubiquinol's 1.7-fold absorption advantage was not statistically significant. A 2026 trial of a cocrystal ubiquinol did find about double the absorption of a standard ubiquinone. The honest summary is that ubiquinol may absorb better, sometimes, depending on the product, and no trial has shown one form produces better health outcomes than the other.

Dose context matters more than form here. Most CoQ10 outcome trials used 100 to 300 mg a day. The best-known, Q-SYMBIO in 2014, gave 300 mg of ubiquinone daily for two years to 420 heart failure patients and reported fewer major cardiovascular events. This product has 40 mg. That is a maintenance-style dose, not a trial dose. It may suit someone topping up, but it is not the dose the heart failure evidence rests on. And there is no published trial of this product's CoQ10 absorption. The D3 study cannot tell us anything about the CoQ10 in the same packet.

The combination question nobody has answered

The synergy story is biologically plausible, but plausibility is not evidence. There is no published trial randomizing people to D3 plus K2 versus D3 alone and measuring fractures, bone density, or artery calcification. AVADEC tested MK-7 plus D against placebo, so it cannot separate the K2 effect from the D effect. Until someone runs that trial, "better together" is a mechanism, not a finding. The same applies to adding CoQ10. There is no trial of this three-ingredient combination for any outcome. If you buy this product, you are buying three reasonable ingredients and one good absorption study, not a proven combination.

Price and value

A box of 28 packets lists at $76. One-time purchase is $60.80, which is $2.17 a packet. The first subscription box is $54.72, or $1.95 a packet, and it renews at $68.40, or $2.44 a packet. The 90-day plan is $48.64 a box, or $1.74 a packet. There is a 60-day money-back guarantee. Since November 2026 it is also in Walmart in 12-packet boxes from $29.99 to $34.99, about $2.50 to $2.92 a packet. Prices change, so check the current price on the product page. The product page shows a rating of 4.9 out of 5 from 2,578 reviews, and 99% would recommend it. If you want to look at it, here is my affiliate link: https://shop.cymbiotika.com/SFVM9DY9. There is no discount code for Cymbiotika, so do not go looking for one. The link is the way to find the product.

Compare that with a good D3 plus K2 capsule, which costs roughly $0.15 to $0.40 a day. You are paying roughly five to ten times that for liposomal delivery, the liquid format, and the CoQ10. The absorption study gives that premium more support than most liposomal products have, but the premium buys better absorption of a dose that is already at the upper limit, not a better health outcome that has been demonstrated.

Worth it if you absorb poorly, for example with gut issues or a low-fat diet, if you hate pills, if you want one packet instead of three bottles, or if you value the convenience and the study behind it. Not worth it if you just need to keep your vitamin D topped up, in which case a plain D3 capsule, plus a separate K2 if you want it, costs a fraction.

Safety and who should be careful

Blood thinners are the main concern. Vitamin K interferes with warfarin and other vitamin K antagonists. If you take a blood thinner, do not start a K2 supplement without talking to your prescriber. People with kidney disease, kidney stones, high blood calcium, sarcoidosis, or other calcium disorders should talk to a clinician first, because 4,000 IU of D3 raises calcium absorption. Add up all your vitamin D sources. The upper limit is 4,000 IU a day from everything combined. In pregnancy and breastfeeding, dose should be decided with a clinician, even though the guideline supports vitamin D in pregnancy. CoQ10 is often taken alongside statins and is generally well tolerated, but tell your clinician. Side effects are uncommon at this dose: occasional nausea, constipation, or headache.

Verdict

This is the most evidence-backed product in Cymbiotika's Core Four so far, and that is not a low bar. It has a real, published, randomized trial of the actual product, showing about double the D3 absorption of a standard tablet over 48 hours. That is genuinely unusual for a supplement. The trial is small, short, company-funded, and it measures absorption, not health. The K2 dose is generous and the bone-marker evidence is real, but the artery story is mixed and the combination has never been tested against D3 alone. The CoQ10 is a small dose in a form whose advantage is unsettled. At about $2 a packet, you are paying for delivery and convenience. If you want the best-absorbed D3 you can buy and you like the one-packet routine, this is a fair choice with honest evidence behind the delivery claim. If you want proven health benefits per dollar, a plain D3 capsule still wins.

Frequently asked questions

Does liposomal vitamin D3 absorb better than regular vitamin D3?

In the one published trial of this product, yes, over 48 hours. Total D3 exposure was about 1.9 times higher than a matched tablet, and levels stayed above baseline at 48 hours while the tablet arm returned to baseline. It was a single dose in 12 healthy adults, measuring D3 in the blood rather than long-term vitamin D status.

Is 4,000 IU of vitamin D3 too much to take every day?

It is the adult tolerable upper intake level, not the recommended amount. The recommended intake is 600 IU to age 70 and 800 IU after. Taking 4,000 IU is within the established ceiling, but it leaves no room for other D3 sources, so add up everything you take and consider a blood test.

Do I need vitamin K2 with vitamin D3?

No trial has shown D3 plus K2 beats D3 alone for fractures or artery calcification. K2 on its own has reasonable evidence for bone turnover markers and mixed evidence for slowing artery calcification. The combination makes biological sense, but it is unproven.

What is the difference between MK-4 and MK-7?

Both are forms of vitamin K2. MK-7 stays in the blood for days, while MK-4 lasts hours, which is why most trials use MK-7. This product includes both. The label gives a combined 620 mcg and does not split it between the two forms.

Is ubiquinol CoQ10 better than ubiquinone?

The trials disagree. Some found ubiquinol absorbed better, others found no significant difference, and the deciding factor in the best head-to-head study was how the product was formulated, not which form was on the label. No trial has shown one form produces better health outcomes. This product has 40 mg, well below the 100 to 300 mg used in most CoQ10 trials.

Can I take this with a blood thinner?

Not without your prescriber's approval. Vitamin K interferes with warfarin and similar drugs, and the K2 dose here is substantial. Bring the label to your prescriber and ask.

How much does it cost per day?

One box of 28 packets lists at $76. That is $2.17 a packet one-time, $1.95 a packet on the first subscription box, and $1.74 a packet on the 90-day plan. The subscription renews at $68.40 a box, or $2.44 a packet, after the first box. There is no discount code for Cymbiotika. The affiliate link on this page is the way to find the product: https://shop.cymbiotika.com/SFVM9DY9.

Sources

  1. Enhanced acute absorption of vitamin D3 with a liposomal formulation (Cymbiotika) compared to a standard formulation in healthy adults: a randomized double-blind crossover study. Frontiers in Nutrition, 2026. doi:10.3389/fnut.2026.1858064. Trial registration ISRCTN39055102.
  2. Zhang Z, Li Y, Li J, Yuan Y, Liu K, Shi X. The effect of vitamin K2 supplementation on bone turnover biochemical markers in postmenopausal osteoporosis patients: a systematic review and meta-analysis. Frontiers in Endocrinology, 2025. doi:10.3389/fendo.2025.1703116.
  3. Diederichsen ACP et al. Vitamin K2 and D in patients with aortic valve calcification: a randomized double-blinded clinical trial (AVADEC). Circulation, 2022. doi:10.1161/CIRCULATIONAHA.121.057008.
  4. Hasific S et al. Effects of vitamin K2 and D supplementation on coronary artery disease in men: a randomized clinical trial. JACC: Advances, 2023. doi:10.1016/j.jacadv.2023.100643.
  5. Li T, Wang Y, Tu WP. Vitamin K supplementation and vascular calcification: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Nutrition, 2023. PMID 37252246.
  6. Demay MB et al. Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 2024.
  7. Lopez-Lluch G et al. Coenzyme Q10 bioavailability. Nutrition, 2019; Mantle D, Dybring A. Coenzyme Q10 bioavailability. Antioxidants, 2020.
  8. Mortensen SA et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO, a randomized double-blind trial. JACC: Heart Failure, 2014.
  9. National Institutes of Health, Office of Dietary Supplements. Vitamin D: fact sheet for health professionals. Recommended intakes and upper limits.
  10. Cymbiotika. Liposomal Vitamin D3 + K2 + CoQ10 product page. https://cymbiotika.com/en-us/products/d3 (accessed Nov 14, 2026, for product facts, price, rating, and Supplement Facts).

This article is for general information only and is not medical advice. It reports on published studies and does not recommend any supplement, dose, or treatment. Talk to your clinician before starting a new supplement, especially if you take a blood thinner, have kidney disease or a calcium disorder, or are pregnant or breastfeeding.

Not sure where to start?

Take the 30-second protocol finder

Pick your biggest concern — get 3 vetted products with discount codes built in.

Find my protocol